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The toxicity observed in both schedules is summarized in 
table 1. 
Table 1: 
 
 
 
Conclusions: The treatment planification of HDR 
brachytherapy with CT images and 3D dosimetry allows to 
know the dose received in the volume of the organs at risk 
and also a good optimisation of the treatment. 
The treatment was very well tolerated and there was no 
grade 3-4 toxicity in our patients.  
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Purpose/Objective: Toxicity evaluation of exclusive adjuvant 
vaginal cuff High Dose Rate Brachytherapy (HDR-BT) in 
patients with endometrial cancer. 
Materials and Methods: From 2009 to date, 53 patients were 
treated in our institution with HDR-BT, with a median age of 
65 years. 52 patients underwent hysterectomy for 
endometrioid cancer and 1 for transitional cell carcinoma. 
FIGO and grading staging were 14-IA, 35-IB, 4-IIA, 8-G1, 31-
G2, 14-G3. No patients received external-beam radiation 
therapy or chemotherapy. Before Computed Tomography (CT) 
simulation, women underwent a gynecological examination in 
order to determine the size of the vaginal cylinder that will 
fit the patient. CT simulation was performed with 2.5 mm CT 
slice thickness with empty rectum and the treatment cylinder 
in the vaginal cavity. Before CT scan patients drank 500 cc of 
water after voiding bladder ; this preparation was repeated 
before each fraction in order to reproduce bladder's filling 
conditions used for the planning. Upper 3-3.5 cm of the 
vaginal vault were treated. Patients received five fractions 
each of 600 cGy for a total dose of 3000 cGy prescribed at 
0.5 cm from the applicator surface. During the radiation 
therapy course, patients received supportive therapy with 
hyaluronic acid vaginal suppositories. A low-fat diet with the 
addition of lactobacilli was suggested. Use of vaginal dilators 
was not prescribed. Gastrointestinal (GI) and Genitourinary 
(GU) toxicity were evaluated by RTOG score. Late toxicity 
effects were also analysed in 26 patients with a median 
follow-up of 37 months by using the RTOG late-effect score. 
According to our protocol, gynaecological exams were 
scheduled every 3 months for two years and then every 6 
months up to five years. 
Results: Eighteen patients experienced acute GU toxicity: 10 
Grade 1 (G-1), 6 G-2, and 2 G-3. Regarding early GI toxicity, 
9 cases of G-1 toxicity and 2 of G-2 occurred.Four patients 
experienced GU late toxicity: 3 G-2 and 1 G-3. No one 
complained of GI late toxicity. Ten patients presented 
vaginal stenosis during the gynaecological examinations. This 
side effect made the patients' follow-up difficult because of 
greater difficulty in viewing the vaginal vault; also four 
women complained of dyspareunia 
Conclusions: In our experience, vaginal-vault HDR-BT 
treatment is well tolerated, with a very low GI toxicity score. 
Vaginal stenosis appears to be the principal disorder observed 
in long-term follow-up. In order to improve this safe 
technique, we think that could be reasonable to prescribe 
the use of the vaginal dilator not in all patients, but only in 
those women in which the stenosis occur. 
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Purpose/Objective: The aim of this study was to assess 
through radiobiological evaluation the ability of the hybrid 
inverse planning optimization (HIPO) system to produce dose 
distributions comparable or superior to the clinically 
accepted ones devised using graphical optimization (GRO) for 
cervical cancer patients treated with pulsed-dose-rate 
brachytherapy. 
Materials and Methods: Six cervical cancer patients treated 
with external radiotherapy and pulsed-dose-rate 
brachytherapy were included in this study. The patients 
received 50 Gy (25 x 2 Gy) as external radiotherapy and 24 
Gy (3 x 8 Gy) as pulsed-dose-rate brachytherapy planned 
using GRO performed in Oncentra® Brachy treatment 
planning (Nucletron, an Elekta Company). An alternative 
brachytherapy plan was made in HIPO using volumetric 
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constraints and setting different optimization priorities for 
the target and the bladder, rectum and sigmoid colon as 
organs at risk (OARs). The resulting plans were evaluated 
with respect to dosimetric parameters and the plan 
conformity index. The probability of controlling the tumour 
and the normal tissue complication probabilities for each OAR 
were also determined for each plan and patient, as well as 
the probability of cure without complication, P+. 
Results: The dosimetric and volumetric comparison of the 
GRO and HIPO plans in terms of D90, D98, and D2cm3 for rectum, 
bladder and the sigmoid colon rendered similar results. The 
plan conformity expressed as COIN index was also similar for 
the two plans, the average value for the GRO being 0.541, 
and for HIPO 0.595, respectively. For all GRO and HIPO 
brachytherapy plans evaluated together with the external 
beam plans the P+ values, calculated as TCP – NTCP for one of 
the OARs, bladder, rectum and sigmoid colon, at the time, 
were above 0.89. The percent variation of the average P+, 
between GRO and HIPO plans was -0.5%, 2.1% and 1.6% for 
the bladder, rectum and sigmoid, respectively. The results 
indicate that the HIPO plan was only marginally inferior to 
the GRO plan with respect to the probability of controlling 
the tumour weighted against the probability of causing 
bladder complication with a negative difference in P+ of 
0.5%, while with respect to the rectum and the sigmoid 
column the HIPO plan was slightly superior to GRO with an 
excess of P+ of 2.1% and 1.6% respectively. 
Conclusions: The HIPO approach for performing inverse 
planning in brachytherapy renders plans comparable to the 
graphically optimised ones as assessed with the use of 
radiobiological parameters sensitive to small differences in 
the dose distribution, such as the probability of cure without 
complication, P+. 
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Purpose/Objective: To retrospectively assess the incidence 
and clinical characteristics of patients with uterine 
perforation during image-guided intracavitary High-Dose-Rate 
(HDR) brachytherapy for carcinoma of the cervix. 
Materials and Methods: Patients with cervix cancer treated 
with image-guided HDR brachytherapy from February 2006 to 
December 2012 were retrospectively identified. All 
applications were performed without radiological guidance 
for uterine tandem insertion. CT images were analyzed for 
uterine perforation or near-perforation (sub-serosal insertion 
of tandem, i.e. within 5 mm from the uterine serosa). 
Patient's demographic and clinical data were collected and 
their correlation with the incidence of perforation was 
assessed by logistic regression analysis. 
Results: A total of 231 brachytherapy CT-guided applications 
for 82 patients were reviewed. We identified 34 (14.7%) 
treatment plans with sub-optimal insertion of intra-uterine 
tandem in 20 (24.4%) patients: 14 (6%) applications with 
uterine perforation and 20 (8.6%) applications with sub-
serosal insertion of tandem. Four patients (4.8%) presented 
both uterine perforation and sub-serosal insertion. 
Figure 1. Examples of uterine perforation (a) and sub-serosal 
insertion of intra-uterine tandem (b), in sagittal and coronal 
views. 
a. 
 
b. 
 
 
Although it has been noticed a correlation between patient's 
age (median 55.5 years) and advanced disease stage (IIB and 
IIIB) and the incidence of a sub-optimal insertion of intra-
uterine tandem, the logistic regression analysis showed that 
only the stage could be a predictor for a sub-optimal implant 
(p = 0.005), but not the age (p = 0.18).  
Due to limited data regarding the initial and residual tumor 
volume post EBRT, its relation to the incidence of sub-
optimal implants could not be analyzed.  
Table 1. Patient characteristics (n = 82) 
